Regen BioPharma Statistics
Total Valuation
Regen BioPharma has a market cap or net worth of 935,474. The enterprise value is 1.90 million.
| Market Cap | 935,474 |
| Enterprise Value | 1.90M |
Important Dates
The next estimated earnings date is Tuesday, July 22, 2025.
| Earnings Date | Jul 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Regen BioPharma has 21.55 million shares outstanding. The number of shares has increased by 123.69% in one year.
| Current Share Class | 21.55M |
| Shares Outstanding | 21.55M |
| Shares Change (YoY) | +123.69% |
| Shares Change (QoQ) | +424.41% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | n/a |
| Float | 21.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.95 |
| PB Ratio | -0.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.68 |
| EV / Sales | 8.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.69% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 6.48% |
| Revenue Per Employee | 236,561 |
| Profits Per Employee | -1.13M |
| Employee Count | 1 |
| Asset Turnover | 1.52 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.16% in the last 52 weeks. The beta is 3.56, so Regen BioPharma's price volatility has been higher than the market average.
| Beta (5Y) | 3.56 |
| 52-Week Price Change | -93.16% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 45.45 |
| Average Volume (20 Days) | 16,868 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.44 |
Income Statement
In the last 12 months, Regen BioPharma had revenue of 236,561 and -1.13 million in losses. Loss per share was -0.07.
| Revenue | 236,561 |
| Gross Profit | 236,561 |
| Operating Income | -369,063 |
| Pretax Income | -1.13M |
| Net Income | -1.13M |
| EBITDA | n/a |
| EBIT | -369,063 |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 1,761 in cash and 967,632 in debt, giving a net cash position of -965,871 or -0.04 per share.
| Cash & Cash Equivalents | 1,761 |
| Total Debt | 967,632 |
| Net Cash | -965,871 |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -5.70M |
| Book Value Per Share | -0.26 |
| Working Capital | -5.72M |
Cash Flow
| Operating Cash Flow | -489,092 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -156.01% |
| Pretax Margin | -479.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -156.01% |
| FCF Margin | n/a |
Dividends & Yields
Regen BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -123.69% |
| Shareholder Yield | n/a |
| Earnings Yield | -121.29% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 4, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Nov 4, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Regen BioPharma has an Altman Z-Score of -219.13. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -219.13 |
| Piotroski F-Score | n/a |